Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study

CME Activity Information
Release Date:	April 7, 2008
Most Recent Review:	April 7, 2008*
Most Recent Update:	April 7, 2008
Date Credit Expires:	April 7, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 7, 2010, in order to receive the credit or participation certificate.

1. Discuss the importance of treating patients with bone metastases using a multidisciplinary approach.
2. Explain why bisphosphonates are a fundamental part of bone metastasis treatment.
3. Evaluate the main features of ONJ and, in particular, its high risk factor.
4. Describe the importance of ONJ prevention during bisphosphonate treatment.
5. Emphasize the importance of interaction among the patient’s dentist, surgeon, and oncologist for the management of ONJ.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Senior Oncologist and Coordinator of Osteo-Oncology Center, and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Francesca Barbanti, M.D.

Credentials: Dental Surgeon, Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Gianluca Giorgio-Marrano, M.D.

Credentials: Dental Surgeon, Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Laura Mercatali, B.Sc.

Credentials: Research Biologist, Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Sonia Ronconi, M.D.

Credentials: Senior Oncohematologist, Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Claudio Vicini, M.D.

Credentials: Director of Otorinolaryngology Unit, Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

Dino Amadori, M.D.

Credentials: Scientific Director, Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of zoledronic acid, manufactured by Novartis, for the treatment of bone metastases. The author has indicated no relevant commercial relationships.

• Take this course